Eton Pharmaceuticals Inc (ETON)

Currency in USD
17.050
-0.090(-0.53%)
Closed·
After Hours
17.0500.000(0.00%)
·

ETON Financial Summary

Key Ratios

P/E Ratio-109.84
Price/Book19.18
Debt / Equity128.1%
Return on Equity-22.06%
Dividend Yield0.00%
EBITDA-1.11M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30.000
(+75.95% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
0.03 / 0.01
Revenue / Forecast
18.90M / 16.71M
EPS Revisions
Last 90 days

FAQ

What were Eton Pharmaceuticals's earnings for the latest quarter?

The Eton Pharmaceuticals EPS (TTM) is -0.16. Eton Pharmaceuticals reported sales of 18.93, net income of -2.59, and EPS of 0.03 for the latest quarter.

What was Eton Pharmaceuticals's net income for the latest quarter?

Eton Pharmaceuticals's net income for the latest quarter was -2.59.

How did Eton Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 17.28 in the previous quarter to 18.93 in the latest quarter, and net income moved from -1.57 to -2.59 compared to the previous quarter.

What is Eton Pharmaceuticals's net profit margin on a TTM basis?

Eton Pharmaceuticals's trailing twelve months (TTM) net profit margin is -9.80%.

How does Eton Pharmaceuticals's debt to equity ratio compare to industry standards?

Eton Pharmaceuticals's total debt-to-equity ratio is 128.10%.

What is Eton Pharmaceuticals's return on investment on a TTM basis?

Eton Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is -22.06%.

Did Eton Pharmaceuticals gain or lose cash last quarter?

In the latest quarter, Eton Pharmaceuticals's net change in cash was 7.96 million.

What were Eton Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Eton Pharmaceuticals reported total assets of 101.68 million and total liabilities of 38.60 million.

How has Eton Pharmaceuticals's total revenue grown this year?

Eton Pharmaceuticals's total revenue was 17.28 in the previous quarter and 18.93 in the latest quarter.

What is Eton Pharmaceuticals's gross margin on a TTM basis?

Eton Pharmaceuticals's trailing twelve months (TTM) gross margin is 63.44%.

What was Eton Pharmaceuticals's revenue per share for the latest quarter?

Eton Pharmaceuticals's revenue per share for the latest quarter was 44.12.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.